Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674159 | 0.83 | AKT1 (0.70) | AKT1AKT2 | |
| SCHEMBL15183439 | 0.80 | AKT1 (1.00) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL530618 | 0.79 | AKT1 (0.98) | AKT1AKT2 | |
| SCHEMBL15183442 | 0.78 | AKT1 (1.00) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL526433 | 0.77 | AKT1 (0.98) | AKT1AKT2 | |
| SCHEMBL10280378 | 0.75 | AKT1 (0.67) | AKT1AKT2 | |
| SCHEMBL530989 | 0.73 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL538481 | 0.73 | AKT1 (0.59) | AKT1AKT2 | |
| SCHEMBL1351523 | 0.73 | AKT1 (0.62) | AKT1AKT2 | |
| SCHEMBL16564541 | 0.73 | AKT1 (0.88) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171465-A1 | AKT INHIBITORS | Stablix, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4066823-B1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM ST FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (IT) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024264070-A2 | AKT INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20220313694-A1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2022-10-06 | — | — | US | disclosed |
| EP-4066823-A1 | REDUCED CALORIC INTAKE AND ANTICANCER AGENTS FOR THE TREATMENT OF CANCER | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171465-A1 | AKT INHIBITORS | PIK3CA, PIK3CD, PIK3CG | AKT1 5/4885AKT2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.